Abstract
Though we may still sing today, as did Pindar in his eighth Olympian Victory Ode, “… of no contest greater than Olympia, Mother of Games, gold-wreathed Olympia…”, we must sadly admit that today, besides blatant over-commercialization, there is no more ominous threat to the Olympic games than doping. Drug-use methods are steadily becoming more sophisticated and ever harder to detect, increasingly demanding the use of complex analytical procedures of biotechnology and molecular medicine. Special emphasis is thus given to anabolic androgenic steroids, recombinant growth hormone and erythropoietin as well as to gene doping, the newly developed mode of hormones abuse which, for its detection, necessitates high-tech methodology but also multidisciplinary individual measures incorporating educational and psychological methods. In this Olympic year, the present review offers an update on the current technologically advanced endocrine methods of doping while outlining the latest procedures applied—including both the successes and pitfalls of proteomics and metabolomics—to detect doping while contributing to combating this scourge.
Similar content being viewed by others
References
D.H. Catlin, T.H. Murray, Performance-enhancing drugs, fair competition, and Olympic sport. J. Am. Med. Assoc. 276(3), 231–237 (1996)
L.H. Duntas, C. Parisis, Doping: a challenge to the endocrinologist. A reappraisal in view of the Olympic games of 2004. Hormones (Athens) 2(1), 35–42 (2003)
P.L. Toutain, Veterinary medicines and competition animals: the question of medication versus doping control. Handb. Exp. Pharmacol. 199, 315–339 (2010)
H.M. Prendergast, T. Bannen, T.B. Erickson, K.R. Honore, The toxic torch of the modern Olympic games. Vet. Hum. Toxicol. 45(2), 97–102 (2003)
M. Thevis, P. Hemmersbach, H. Geyer, W. Schänzer, Doping in disabled sports. Doping control activities at the Paralympic games 1984–2008 and in Germany 1992–2008. Med. Klin. (Munich) 104(12), 918–924 (2009)
M. Thevis, T. Kuuranne, H. Geyer, W. Schänzer, Annual banned-substance review: analytical approaches in human sports drug testing. Drug Test Anal. 4(1), 2–16 (2012)
M. Kamber, Development of the role of national anti-doping organisations in the fight against doping: from past to future. Forensic Sci. Int. 213(1–3), 3–9 (2011)
L. Di Luigi, F. Romanelli, P. Sgrò, A. Lenzi, Andrological aspects of physical exercise and sport medicine. Endocrine 59(6):503–508 [Epub ahead of print] (2012)
C. Saudan, N. Baume, N. Robinson, L. Avois, P. Mangin, M. Saugy, Testosterone and doping control. Br. J. Sports Med. 40, i21–i24 (2006)
E.T. Keller, W.B. Ershler, C. Chang, The androgen receptor: a mediator of diverse responses. Front. Biosci. 1(1), d59–d71 (1996)
C.A. Heinlein, C. Chang, Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23(2), 175–200 (2002)
A.B. Cadwallaber, C.S. Lim, D.E. Rollins, F. Botrè, The androgen receptor and its use in biological assays: looking toward effect-based testing and its applications. J. Anal. Toxicol. 35(9), 594–607 (2011)
F. Sjöqvist, M. Garle, A. Rane, Use of doping agents, particularly anabolic steroids, in sports and society. Lancet 371(9627), 1872–1882 (2008)
NIDA, National Institute on Drug Abuse Research Report Series: Anabolic Steroid Abuse (NIDA, Bethesda, 2006)
C.J. Bagatell, W.J. Bremner, Androgens in men—uses and abuses. N. Engl. J. Med. 334(11), 707–714 (1996)
R.C. Hall, R.C. Hall, Abuse of supraphysiologic doses of anabolic steroids. South. Med. J. 98(5), 550–555 (2005)
F. Hartgens, H. Kuipers, Effects of androgenic–anabolic steroids in athletes. Sports Med. 34(8), 513–554 (2004)
A.H. Beckett, D.A. Cowan, Misuse of drugs in sport. Br. J. Sports Med. 12(4), 185–194 (1978)
O.J. Pozo, P. Van Eenoo, K. Deventer, L. Lootens, S. Grimalt, J.V. Sancho, F. Hernández, P. Meuleman, G. Leroux-Roels, F.T. Delbeke, Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry. Steroids 74(10–11), 837–852 (2009)
A. Brinkmann, G.G. Kuiper, W. de Boer, E. Mulder, J. Bolt, G.J. Van Steenbrugge, H.J. van der Molen, Characterization of androgen receptors after photoaffinity labelling with [3H]methyltrienolone (R1881). J. Steroid Biochem. 24(1), 245–249 (1986)
L.M. Irving, M. Wall, D. Neumark-Sztainer, M. Story, Steroid use among adolescents: findings from project EAT. J. Adolesc. Health 30(4), 243–252 (2002)
G. Kanayama, J.I. Hudson, H.G. Jr, Pope, long-term psychiatric and medical consequences of anabolic–androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend. 98(1–2), 1–12 (2008)
T.A. Pagonis, N.V. Angelopoulos, G.N. Koukoulis, C.S. Hadjichristodoulou, Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. Eur. Psychiatry 21(8), 551–562 (2006)
M. Montisci, R. El Mazloum, G. Cecchetto, C. Terranova, S.D. Ferrara, G. Thiene, C. Basso, Anabolic androgenic steroids abuse and cardiac death in athletes: morphological and toxicological findings in four fatal cases. Forensic Sci. Int. 217(1–3), e13–e18 (2012)
G. Lippi, G. Banfi, Doping and thrombosis in sports. Semin. Thromb. Hemost. 37(8), 918–928 (2011)
U. Mareck, H. Geyer, G. Opfermann, M. Thevis, W. Schänzer, Factors influencing the steroid profile in doping control analysis. J. Mass Spectrom. 43(7), 877–891 (2008)
J.P. Danaceau, M.S. Morrison, M.H. Slawson, Quantitative confirmation of testosterone and epitestosterone in human urine by LC/Q-ToF mass spectrometry for doping control. J. Mass Spectrom. 43(7), 993–1000 (2008)
B. Maralikova, W. Weinmann, Confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography-tandem mass spectrometry with respect to criteria for compound identification. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 811(1), 21–30 (2004)
R. Aguilera, C.K. Hatton, D.H. Catlin, Detection of epitestosterone doping by isotope ratio mass spectrometry. Clin Chem. 48(4), 629–636 (2002)
I. Athanasiadou, Y.S. Angelis, E. Lyris, A. Vonaparti, N.S. Thomaidis, M.A. Koupparis, C. Georgakopoulos, Two-step derivatization procedures for the ionization enhancement of anabolic steroids in LC–ESI–MS for doping control analysis. Bioanalysis 4(2), 167–175 (2012)
M. Thevis, A. Thomas, M. Kohler, S. Beuck, I. Möller, M. Schäfer, G. Rodchenkov, S. Yin, J.A. Loo, H. Geyer, W. Schänzer, Mass spectrometry-based characterization of new drugs and methods of performance manipulation in doping control analysis. Eur. J. Mass Spectrom. 16(3), 301–312 (2010)
H.M. Pereira, M.C. Padilha, F.R. Neto, Tetrahydrogestrinone analysis and designer steroids revisited. Bioanalysis 1(8), 1475–1489 (2009)
P. Teale, J. Scarth, S. Hudson, Impact of the emergence of designer drugs upon sports doping testing. Bioanalysis 4(1), 71–88 (2012)
M.K. Parr, G. Opfermann, H. Geyer, F. Westphal, F.D. Sönnichsen, J. Zapp, D. Kwiatkowska, W. Schänzer, Seized designer supplement named “1-androsterone”: identification as 3β-hydroxy-5α-androst-1-en-17-one and its urinary elimination. Steroids 76(6), 540–547 (2011)
C. Gómez, O.J. Pozo, H. Geyer, J. Marcos, M. Thevis, W. Schänzer, J. Segura, R. Ventura, New potential markers for the detection of boldenone misuse. Steroid Biochem. Mol. Biol. 132(3–5):239–246 (2012) [Epub ahead of print]
S. Guddat, G. Fußhöller, H. Geyer, A. Thomas, H. Braun, N. Haenelt, A. Schwenke, C. Klose, M. Thevis, W. Schänzer, Clenbuterol: regional food contamination a possible source for inadvertent doping in sports. Drug Test Anal. 4(6), 534–538 (2012)
E. Strahm, P.E. Sottas, C. Schweizer, M. Saugy, J. Dvorak, C. Saudan, Steroid profiles of professional soccer players: an international comparative study. Br. J. Sports Med. 43(14), 1126–1130 (2009)
J.J. Schulze, J. Lundmark, M. Garle, I. Skilving, L. Ekström, A. Rane, Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J. Clin. Endocrinol. Metab. 93(7), 2500–2506 (2008)
A. Rane, L. Ekström, Androgens and doping tests: genetic variation and pit-falls. Br. J. Clin. Pharmacol. 74(1), 3–15 (2012)
J.J. Schulze, J. Lundmark, M. Garle, L. Ekström, P.E. Sottas, A. Rane, Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests. Steroids 74(3), 365–368 (2009)
C. Quan, F. Su, H. Wang, H. Li, Development of anabolic–androgenic steroids purity certified reference materials for anti-doping. Steroids 76(14), 1527–1534 (2011)
J.C. Rijk, A. Lommen, M.L. Essers, M.J. Groot, J.M. Van Hende, T.G. Doeswijk, M.W. Nielen, Metabolomics approach to anabolic steroid urine profiling of bovines treated with prohormones. Anal. Chem. 81(16), 6879–6888 (2009)
K.K. Ho, Diagnosis and management of adult growth hormone deficiency. Endocrine 12(2), 189–196 (2000)
J. Gibney, J.D. Wallace, T. Spinks, L. Schnorr, A. Lanicar, R.C. Cuneo, S. Lockhart, K.G. Burnand, F. Salomon, P.H. Sonksen, D. Russell-Jones, The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 84(8), 2596–2602 (1999)
G. Götherström, B.A. Bengtsson, I. Bosaeus, G. Johansson, J. Svensson, A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J. Clin. Endocrinol. Metab. 92(4), 1442–1445 (2007)
W.M. Widdowson, J. Gibney, The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J. Clin. Endocrinol. Metab. 93(11), 4413–4417 (2008)
W.M. Widdowson, J. Gibney, The effect of growth hormone (GH) replacement on muscle strength in patients with GH-deficiency: a meta-analysis. Clin. Endocrinol. (Oxf) 72(6), 787–792 (2010)
M. Gola, S. Bonadonna, M. Doga, A. Giustina, Clinical review: growth hormone and cardiovascular risk factors. J. Clin. Endocrinol. Metab. 90(3), 1864–1870 (2005)
H. Liu, D.M. Bravata, I. Olkin, A. Friedlander, V. Liu, B. Roberts, E. Bendand, O. Saynina, S.R. Salpeter, A.M. Garber, A.R. Hoffman, Systematic review: the effects of growth hormone on athletic performance. Ann. Intern. Med. 148(10), 747–758 (2008)
K.E. Yarasheski, J.J. Zachweija, T.J. Angelopoulos, D.M. Bier, Short-term growth hormone treatment does not increase muscle protein synthesis in experienced weight lifters. J. Appl. Physiol. 74(6), 3073–3076 (1993)
A.L. Carrel, D.B. Allen, Effects of growth hormone on body composition and bone metabolism. Endocrine 12(2), 163–172 (2000)
V. Birzniece, U.J. Meinhart, M.A. Umpleby, D.J. Hanlesman, K.K. Ho, Interaction between testosterone and growth hormone on whole-body protein anabolism occurs in the liver. J. Clin. Endocrinol. Metab. 96(4), 1060–1067 (2011)
V. Birzniece, A.E. Nelson, K.K. Ho, Growth hormone administration: is it safe and effective for athletic performance. Endocrinol. Metab. Clin. North Am. 39(1), 11–23 (2010)
A. Berggren, C. Ehrnborg, T. Rosén, L. Ellegård, B.A. Bengtsson, K. Caidahl, Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes. J. Clin. Endocrinol. Metab. 90(6), 3268–3273 (2005)
U. Meinhardt, A.E. Nelson, J.L. Hansen, V. Birniece, D. Clifford, K.C. Leung, K. Graham, K.K. Ho, The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Ann. Int. Med. 152(9), 568–577 (2010)
S. Longobardi, N. Keay, C. Ehrnborg, A. Cittadini, T. Rosén, R. Dall, M.A. Boroujerdi, E.E. Basset, M.L. Healy, C. Pentecost, J.D. Wallace, J. Powrie, J.O. Jorgensen, L. Saccà, Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 study group. J. Clin. Endocrinol. Metab. 85(4), 1505–1512 (2000)
M. Volterrani, P. Desenzani, R. Lorusso, A. d’Aloia, F. Manelli, A. Giustina, Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet 349(9058), 1067–1068 (1997)
M. Saugy, N. Robinson, C. Saudan, N. Baume, L. Avois, P. Mangin, Human growth hormone doping in sport. Br. J. Sports Med. 40(Suppl 1), i35–i39 (2006)
K.K. Ho, A.E. Nelson, Growth hormone in sports: detecting the doped or duped. Horm. Res. Paediatr. 76(Suppl 1), 84–90 (2011)
I. Erotokritou-Mulligan, N. Guha, M. Stow, E.E. Bassett, C. Bartlett, D.A. Cowan, P.H. Sönksen, R.I. Holt, The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays. Growth Horm. IGF Res. 22(2), 53–58 (2012)
L. Di Luigi, A.E. Rigamonti, F. Agosti, M. Mencarelli, P. Sgrò, N. Marazzi, S.G. Cella, E.E. Müller, A. Sartorio, Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes. Eur. J. Endocrinol. 160(5), 753–758 (2009)
A. Sartorio, F. Agosti, N. Marazzi, N.A. Maffiuletti, S.G. Cella, A.E. Rigamonti, L. Guidetti, L. Di Luigi, E.E. Müller, Combined evaluation of resting IGF-I, N-terminal propeptide of type III procollagen (PIIINP) and C-terminal cross-linked telopeptide of type I collagen (ICTP) levels might be useful for detecting inappropriate GH administration in athletes: a preliminary report. Clin Endocrinol (Oxf) 61(4), 487–493 (2004)
J.D. Wallace, R.C. Cuneo, M. Bidlingmaier, P.A. Lundberg, L. Carlsson, C.L. Boguszewski, J. Hay, M.L. Healy, R. Napoli, R. Dall, T. Rosén, C.J. Strasburger, The response of molecular isoforms of growth hormone to acute exercise in trained adult males. J. Clin. Endocrinol. Metab. 86(1), 200–206 (2001)
J.D. Wallace, R.C. Cuneo, M. Bidlingmaier, P.A. Lundberg, L. Carlsson, C.L. Boguszewski, J. Hay, M. Boroujerdi, A. Cittadini, R. Dall, T. Rosén, C.J. Strasburger, Changes in non-22-kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22-kDa recombinant human GH in trained adult males. J. Clin. Endocrinol. Metab. 86(4), 1731–1737 (2001)
M. Bidlingmaier, Z. Wu, C.J. Strasburger, Test method: GH. Baillieres. Best Pract. Res. Clin. Endocrinol. Metab. 14(1), 99–109 (2000)
M. Irie, M. Ueki, Y. Kishikawa, M. Nishii, M. Kawahara, 20 K-GH and its use in detecting GH abuse. Growth Horm. IGF Res. 19(4), 352–356 (2009)
A. Keller, Z. Wu, J. Kratzsch, E. Keller, W.F. Blum, A. Kniess, R. Preiss, J. Teichert, C.J. Strasburger, M. Bidlingmaier, Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. Eur. J. Endocrinol. 156(6), 647–653 (2007)
O. Barroso, P. Schamasch, O. Rabin, Detection of GH abuse in sport: past, present and future. Growth Horm. IGF Res. 19(4), 369–374 (2009)
N. Guha, I. Erotokritou-Mulligan, C. Bartlett, A.D. Cowan, E.E. Bassett, M. Stow, P.H. Sönksen, R.I. Holt, The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal propeptide concentrations: implications for the detection of growth hormone misuse in athletes. Drug Test Anal. 4(6), 455–459 (2012)
I. Erotokritou-Mulligan, E. Basset, D.A. Cowan, C. Bartlett, P. Milward, A. Sartorio, P.H. Sönksen, R.I. Holt, The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score. Clin. Endocrinol. (Oxf.) 72(4), 520–526 (2010)
G. Such-Sanmartín, J. Bosch, J. Segura, R. Gutiérrez-Gallego, Growth hormone abuse and biological passport: is mannan-binding lectin a complementary candidate? Clin. J. Sport Med. 21(5), 441–443 (2011)
N. Guha, I. Erotokritou-Mulligan, C. Burford, G. Stobridge, J. Brigg, T. Drake, E.E. Basset, D. Cowan, C. Bartlett, P.H. Sönksen, R.I. Holt, Serum insulin-like growth factor-I and pro-collagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport. J. Clin. Endocinol. Metab. 95(6), 2969–2976 (2010)
A.E. Nelson, U. Meinhardt, J.L. Hansen, I.H. Walker, G. Stone, C.J. Howe, K.C. Leung, M.J. Siebel, R.C. Baxter, D.J. Handelsman, R. Kazlauskas, K.K. Ho, Pharmacodynamics of growth hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes. J. Clin. Endocrinol. Metab. 93(6), 2213–2222 (2008)
C.J. Mitchell, A.E. Nelson, M.J. Cowley, W. Kaplan, G. Stone, S.K. Sutton, A. Lau, C.M. Lee, K.K. Ho, Detection of growth hormone doping by gene expression profiling of peripheral blood. J. Clin. Endocrinol. Metab. 94(12), 4703–4709 (2009)
J. Ding, E.O. List, S. Okada, J.J. Kopchick, Perspective: proteomic approach to detect biomarkers of human growth hormone. Growth Horm. IGF Res. 19(4), 399–407 (2009)
A. Thomas, M. Kohler, W. Schänzer, P. Delahaut, M. Thevis, Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC–MS/MS. Analyst 136(5), 1003–1012 (2011)
F. Boyard-Kieken, G. Dervilly-Pinel, P. Garcia, A.C. Paris, M.A. Popot, B. le Bizec, Y. Bonnaire, Comparison of different liquid chromatography stationary phases in LC-HRMS metabolomics for the detection of recombinant growth hormone doping control. J. Sep. Sci. 34(24), 3493–3501 (2011)
J.M.J. García, E.T. Sánchez, D.O. Hidalgo, E.A. Conejo, Erythropoietin pharmacology. Clin. Transl. Oncol. 9(11), 715–722 (2007)
R.L. Wilber, Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid. Sports Med. 32(2), 125–142 (2002)
W. Jelkmann, Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr. Pharm. Biotechnol. 1(1), 11–31 (2000)
J. Mørkeberg, Detection of autologous blood transfusions in athletes: a historical perspective. Transfus. Med. Rev. 26(3), 199–208 (2012)
S. Giraud, N. Robinson, P. Mangin, M. Saugy, Scientific and forensic standards for homologous blood transfusion anti-doping analyses. Forensic Sci. Int. 179(1), 22–33 (2012)
S. Elliott, E. Pham, I.C. Macdougall, Erythropoietins: a common mechanism of action. Exp. Haematol. 36(12), 1573–1584 (2008)
J.M. Topf, CERA: third-generation erythropoiesis-stimulating agent. Expert Opin. Pharmacother. 9(5), 839–849 (2008)
G. Lippi, M. Franchini, G.L. Salvagno, G.C. Guidi, Biochemistry, physiology, and complications of blood doping: facts and speculation. Crit. Rev. Clin. Lab. Sci. 43(4), 349–391 (2006)
M. Tsivou, H.A. Dimopoulou, I.P. Leontiou, D.G. Georgakopoulos, M.A. Koupparis, J. Atta-Politou, C.G. Georgakopoulos, Stabilization of human urine doping control samples: III. Recombinant human erythropoietin. Clin. Chim. Acta. 411(5–6), 448–452 (2010)
J.A. Pascual, V. Belalcazar, C. de Bolos, R. Gutiérrez, E. Llop, J. Segura, Recombinant erythropoietin and analogues: a challenge for doping control. Ther. Drug Monit. 26(2), 175–179 (2004)
E. Diamanti-Kandarakis, P.A. Konstantinopoulos, J. Papailiou, S.A. Kandarakis, A. Andreopoulos, G.P. Sykiotis, Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era. Sports Med. 35(10), 831–840 (2005)
C. Lundby, P. Robach, B. Saltin, The evolving science of detection of ‘blood doping’. Br. J. Pharmacol. 165(5), 1306–1315 (2012)
C. Reichel, The overlooked difference between human endogenous and recombinant erythropoietins and its implication for sports drug testing and pharmaceutical drug design. Drug Test Anal. 3(11–12), 883–891 (2011)
C. Reichel, SARCOSYL-PAGE: a new electrophoretic method for the separation and immunological detection of PEGylated proteins. Methods Mol. Biol. 865, 65–79 (2012)
C. Reichel, M. Thevis, Detection of EPO-Fc fusion protein in human blood: screening and confirmation protocols for sports drug testing. Drug Test Anal. doi:10.1002/dta.1381 (2012) [Epub ahead of print]
M. Lönnberg, M. Andrén, G. Birgegård, M. Drevin, M. Garle, J. Carlson, Rapid detection of erythropoiesis-stimulating agents in urine and serum. Anal. Biochem. 420(2), 101–114 (2012)
C. Reichel, OMICS-strategies and methods in the fight against doping. Forensic Sci. Int. 213(1–3), 20–34 (2011)
H. Schwarzenbach, Impact of physical activity and doping on epigenetic gene regulation. Drug Test Anal. 3(10), 682–687 (2011)
WADA, The 2008 Prohibited List (WADA, Montreal, 2008)
C.F. Argüelles, E. Hernández-Zamora, Gene doping: gene transfer and possible molecular detection. Gac. Med. Mex. 143(2), 169–172 (2007)
R.S. Oliveira, T.F. Collares, K.R. Smith, T.V. Collares, F.K. Seixas, The use of genes for performance enhancement: doping or therapy? Braz. J. Med. Biol. Res. 44(12), 1194–1201 (2011)
H.E. Montgomery, R. Marshall, H. Hemingway, S. Myerson, P. Clarkson, C. Dollery, M. Hayward, D.E. Holliman, M. Jubb, M. World, E.L. Thomas, A.E. Brynes, N. Saeed, M. Barnard, J.D. Bell, K. Prasad, M. Rayson, P.J. Talmud, S.E. Humphries, Human gene for physical performance. Nature 393(6682), 221–222 (1998)
N.C. Sharp, The human genome and sport, including epigenetics, gene doping, and athleticogenomics. Endocrinol. Metab. Clin. North Am. 39(1), 201–215 (2010)
E.W.Neuberger, M. Jurkiewicz, D.A. Moser, P. Simon, Detection of EPO gene doping in blood. Drug Test Anal. doi:10.1002/dta.1347 (2012) [Epub ahead of print]
A. Baoutina, I.E. Alexander, J.E. Rasko, K.R. Emslie, Potential use of gene transfer in athletic performance enhancement. Mol. Ther. 15(10), 1751–1766 (2007)
M.M. Mansour, H.M. Azzazy, The hunt for gene dopers. Drug Test Anal. 1(7), 311–322 (2009)
W. Ni, C. Le Guiner, P. Moullier, R.O. Snyder, Development and utility of an internal threshold control (ITC) real-time PCR assay for exogenous DNA detection. PLoS One 7(5), e36461 (2012) [Epub ahead of print]
C. D’Angelo, C. Tamburrini, Addict to win? A different approach to doping. J. Med. Ethics 36(11), 700–707 (2010)
G. Lippi, G. Banfi, M. Franchini, G.C. Guidi, New strategies for doping control. J. Sports Sci. 26(5), 441–445 (2008)
Conflict of interest
There is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Duntas, L.H., Popovic, V. Hormones as doping in sports. Endocrine 43, 303–313 (2013). https://doi.org/10.1007/s12020-012-9794-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-012-9794-9